Complete Genomics will receive $8 million to sequence 500 tumor/normal pairs, or $8,000 per genome, as part of a National Cancer Institute initiative funded by the American Recovery and Reinvestment Act of 2009, the company said this week. The project aims to identify therapeutic targets in childhood cancers.

The contract follows on a previous phase of the project, during which the company sequenced 50 tumor/normal pairs from pediatric cancers, including acute lymphoblastic leukemia, acute myeloid leukemia, neuroblastoma, osteosarcoma, and Wilms tumor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.